Income Statement (Annual)

FMC / FMC Corp. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Adminstrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.

All numbers are times 1,000 except per share units.

2009 2010 2011 2012 2013 2014 2015 2016 2017
Profit Loss 238,800 184,900 382,200 435,700 308,000 322,100 498,500 211,700 538,400
Other Comprehensive Income Loss Net Of Tax Period Increase Decrease
  Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Period Increase Decrease
    Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax 16,900 -26,000 -15,000 2,500 100 -76,500 -97,300 -48,700 172,700
    Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent - - - - - - - - -
  Other Comprehensive Income Derivatives Qualifying As Hedges Net Of Tax Period Increase Decrease
    Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax 7,600 -5,900 -10,300 -200 -4,900 3,100 700 7,300 -1,200
    Other Comprehensive Income Loss Reclassification Adjustment From A O C I On Derivatives Net Of Tax - - - -5,900 -300 900 3,000 -6,000 700
    Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax - -3,400 -3,700 5,700 -4,600 2,200 -2,300 13,300 -1,900
  Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Period Increase Decrease
    Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax - - - - - - - - -
    Other Comprehensive Income Loss Reclassification Adjustment From A O C I Pension And Other Postretirement Benefit Plans For Net Gain Loss Net Of Tax - - - -30,400 -35,900 -22,300 -44,100 -39,200 -51,600
    Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax - 3,500 60,200 26,900 -209,900 151,000 -17,700 -12,300 -52,200
Other Comprehensive Income Loss Net Of Tax - -32,900 -78,900 -18,700 205,400 -175,700 -81,900 -23,100 236,900
Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest 235,200 152,000 303,300 417,000 513,400 146,400 416,600 188,600 775,300
Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest 9,800 12,000 15,700 19,700 12,500 12,800 9,100 600 1,400
Comprehensive Income Net Of Tax 225,400 140,000 287,600 397,300 500,900 133,600 407,500 188,000 773,900

Peers - Chemicals And Allied Products (28)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 302491303